Analysis of the Special Review of Innovative Medical Devices in China

Zhao Nana, Li Xuejiao

Chinese Pharmaceutical Affairs ›› 2025, Vol. 39 ›› Issue (3) : 300-305.

PDF(1094 KB)
PDF(1094 KB)
Chinese Pharmaceutical Affairs ›› 2025, Vol. 39 ›› Issue (3) : 300-305. DOI: 10.16153/j.1002-7777.2024-10-0050
Supervision & Administration

Analysis of the Special Review of Innovative Medical Devices in China

Author information +
History +

Abstract

Objective: To analyze the public disclosure data of innovative medical devices released on the official website of the CMDE from 2014 to August 2024, and to provide reference for colleagues in the medical industry. Methods: Through combing and analyzing the application pass rate, regional distribution and type distribution since 2014, the change trend and common problems were analyzed from the perspective of review, as well as relevant suggestions were put forward. Results: It was found that a total of 535 medical devices were approved into the innovation review process, with a pass rate of 19.25%. Most of the medical devices included in the innovation channel are active and passive products, which are mostly concentrated in the high-end fields with high technical content and urgent clinical needs, most of the applicants are concentrated in Beijing, Shanghai, Guangdong, Jiangsu, Zhejiang 5 regions. The common problems in the volume review process mainly focus on the application form, invention patent, and research and development data. There are many problems in each review requirement in the expert review process. Conclusion: It is suggested that enterprises should pay attention to the training of registered personnel and strengthen the study of relevant laws and regulations, and the regulatory authorities should strengthen the cooperation of all units, and do a good job in the relevant training of evaluation experts and applicants.

Key words

innovative medical devices / special review / volume review / expert review

Cite this article

Download Citations
Zhao Nana, Li Xuejiao. Analysis of the Special Review of Innovative Medical Devices in China[J]. Chinese Pharmaceutical Affairs, 2025, 39(3): 300-305 https://doi.org/10.16153/j.1002-7777.2024-10-0050

References

[1] 国务院. 国发〔2015〕44号关于改革药品医疗器械审评审批制度的意见[S].2015.
[2] 国家食品药品监督管理总局. 食药监械管〔2014〕13号关于发布创新医疗器械特别审批程序(试行)的公告[S].2014.
[3] 国家药品监督管理局. 2018年第83号关于发布创新医疗器械特别审查程序的公告[S].2018.
[4] 国家药品监督管理局医疗器械技术审评中心. 创新优先公示[EB/OL].(2014)[2024-06-20]. https://www.cmde.org.cn/xwdt/shpgzgg/cxyxgsh/index.html.
[5] 国家药品监督管理局医疗器械技术审评中心. 审评状况[EB/OL].(2014)[2024-07-19]. https://www.cmde.org.cn/xwdt/shpzk/index.html.
[6] 国家药品监督管理局医疗器械技术审评中心. 2018年第11号关于发布医疗器械技术审评中心创新医疗器械特别审查申请审查操作规范的通告[S].2018.
[7] 国务院. 国务院令第739号医疗器械监督管理条例[S].2021.
[8] 国家食品药品监督管理总局. 2017年第104号总局关于发布医疗器械分类目录的公告[S].2017.
[9] 国家药品监督管理局医疗器械技术审评中心. 2018年第127号关于发布创新医疗器械特别审查申报资料编写指南的通告[S].2018.
PDF(1094 KB)

35

Accesses

0

Citation

Detail

Sections
Recommended

/